Home Cart Sign in  
Chemical Structure| 870153-29-0 Chemical Structure| 870153-29-0

Structure of PF-00835231
CAS No.: 870153-29-0

Chemical Structure| 870153-29-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF00835231 is a SARS CoV-1 3CLpro inhibitor for potential treatment of COVID-19.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF-00835231

CAS No. :870153-29-0
Formula : C24H32N4O6
M.W : 472.53
SMILES Code : O=C(C(N1)=CC2=C1C=CC=C2OC)N[C@H](C(N[C@@H](C[C@H]3C(NCC3)=O)C(CO)=O)=O)CC(C)C
MDL No. :MFCD33029312
InChI Key :QDIMHKWNHMVDJB-WBAXXEDZSA-N
Pubchem ID :11561899

Safety of PF-00835231

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
PF-00835231 is an inhibitor of the CoV-2 cysteine 3C-like protease (3CLpro), exhibiting IC50 values of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 has been developed for research purposes in the context of anti-SARS-CoV-2/COVID-19 [1].

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa-ACE2 cells 0.13 µM 24 hours Evaluation of PF-00835231's antiviral activity in combination with remdesivir, showing an EC50 of 0.13 µM in HeLa-ACE2 cells PMC8523698
VeroE6-EGFP cells 88.9 µM 5 days Evaluation of PF-00835231's in vitro antiviral activity against SARS-CoV-2, showing an EC50 of 88.9 µM in VeroE6-EGFP cells PMC8523698
VeroE6-enACE2 cells 39.7 µM 3 days Evaluation of PF-00835231's in vitro antiviral activity against SARS-CoV-2, showing an EC50 of 39.7 µM in VeroE6-enACE2 cells PMC8523698
Polarized human airway epithelial cultures (HAEC) 0.025, 0.5, 10 μM 72h Assess the antiviral activity of PF-00835231 in the HAEC model, demonstrating effective inhibition of SARS-CoV-2 PMC8139662
A549+ACE2 cells 0.221 μM (24h), 0.158 μM (48h) 24h and 48h Evaluate the antiviral activity of PF-00835231 against SARS-CoV-2, showing it is more potent than remdesivir PMC8139662
293T cells 1.25 μM 54 hours Evaluate the inhibitory effect of PF-00835231 on SARS-CoV-2 3CLpro, showing typical dose-response inhibition PMC10187092

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice SARS-CoV-MA15 infection model Subcutaneous injection 100 mg/kg Twice daily for 4 days Evaluation of PF-00835231's antiviral efficacy in a SARS-CoV-infected mouse model, showing significant reduction in lung viral titers PMC8523698

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.58mL

2.12mL

1.06mL

21.16mL

4.23mL

2.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories